Our client, a global leader in the creation and commercialization of pioneering therapies for rare genetic diseases, is looking for novel therapeutic approaches targeting TDP-43 pathology. Specifically, the team is interested in strategies that can ameliorate TDP-43 pathology in neurons for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), as well as related diseases.
Approaches should reduce cytoplasmic inclusions of TDP-43 and increase TDP-43 nuclear function in ALS/FTD disease models.
Approaches of Interest:
- Strategies...